The disease affects as many as 80 million in the U.S. alone. Now Apnimed, the $400 million company behind the first ever pill to treat it, is preparing to file for FDA approval. Read the full story on Forbes: https://www.forbes.com/sites/amyfeldman/2026/01/12/a-holy-grail-sleep-apnea-pill-could-be-on-the-market-next-year/ Subscribe to FORBES: https://www.youtube.com/user/Forbes?sub_confirmation=1 Fuel your success with Forbes. Gain unlimited access to premium journalism, including breaking news,